I did comment on your NK post:
"NK. I have followed NK cell bio's for many years now. AFMD, FATE, NKTX, LPTX, etc.
It seems the main problem with NK cells versus T cells is longevity, or the lack of it.
NK cells live a few days to a couple of weeks. B cells for several weeks. T cells for many months or longer.
Or at least that is my general understanding of immune cells."
NK cell research is nothing new and there are many much older and much more advanced NK companies that can be discussed, on their individual prospective boards.
But this is the MRKR board where the posts are generally about or peripheral to MRKR, or are posts that comment on a previous post relative to MRKR.
I don't think there a NK:IO board, but if you wish to, you can start a NK:IO board.
If I was to discuss NK:IO further, as you brought the company up, I would ask you the following questions.
Can you inform me of examples of past performances and accomplishes that have been achieved by UKI2S and Codon and Jonathan Milner and Meltwind?
Can you tell me what you think the patient treatment cost differences will be compared to MRKR for their stem cell wNK:IO human NK cells treatment?
Can you tell me what you think the patient treatment cost differences will be compared to MRKR for their engineered eNK:IO human NK cells Treatment?
Can you tell me what you think about the effectiveness of their dNK:IO REV-ERB Antagonist platform?
Being that their therapeutic programmes are currently at the research/early preclinical stage of development, how long do you think it will be before we get their first phase 1 trial data?
Can you inform me of examples of past performances and accomplishes that have been achieved by
Cell and Gene Therapy Catapult and Deep Science Ventures?
Being that Andrew Baxendale the CEO is an expert in vascular calcification, can you explain how that would be a benefit in the advancement of NK calls?
Being that Hugh Brady is an expert in haematopoiesis, can you explain how that would be a benefit in the advancement of NK calls?
Being that Matthew Fuchter is an expert in kinase target CDK7, can you explain how that would be a benefit in the advancement of NK calls?
OK, there are a dozen or so questions I have concerning NK:IO. I will look forward to your answers to all of those questions after you take all the time you need to do the appropriate research in order to answer them.
